Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06NDP
|
|||
| Former ID |
DIB014753
|
|||
| Drug Name |
CIGB-128
|
|||
| Synonyms |
HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB
Click to Show/Hide
|
|||
| Indication | Basal cell carcinoma [ICD-11: 2C32; ICD-10: C44] | Phase 1 | [1] | |
| Company |
Center for Genetic Engineering and Biotechnology
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037683) | |||
| REF 2 | Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.